Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal
development and contributes to tissue and whole-body homeostasis, but can also promote …

Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the
clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We …

Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases that are
involved in the regulation of cell proliferation, survival, and development. FGFR alterations …

Fibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor
types. Here we studied pemigatinib, a selective, potent, oral FGFR1–FGFR3 inhibitor, in the …

Background Pemigatinib is approved for patients with pretreated, locally advanced or
metastatic CCA harboring FGFR2 rearrangements or fusions. We aim to assess the …

Genomic alterations that activate Fibroblast Growth Factor Receptor 2 (FGFR2) are common
in intrahepatic cholangiocarcinoma (ICC) and confer sensitivity to FGFR inhibition. However …

Background Futibatinib is the only covalent inhibitor of FGFR1-4 to gain regulatory approval
in oncology. Here, we present genomic analyses of tissue biopsies and circulating tumor …

Background Fibroblast growth factor receptor (FGFR) inhibitors have significantly improved
outcomes for patients with FGFR-altered cholangiocarcinoma, leading to their regulatory …

The challenge of drug resistance in intrahepatic cholangiocarcinoma (ICC) is intricately
linked with lipid metabolism reprogramming. The hepatic lipase (HL) and the membrane …

Cholangiocarcinoma (CCA) is an aggressive bile duct malignancy with heterogeneous
genomic features. While most patients receive standard-of-care chemo/immunotherapy …